ILC2s: New Actors in Tumor Immunity.

Details

Ressource 1Download: 31849977_BIB_24E7A73B150C.pdf (1519.96 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_24E7A73B150C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
ILC2s: New Actors in Tumor Immunity.
Journal
Frontiers in immunology
Author(s)
Ercolano G., Falquet M., Vanoni G., Trabanelli S., Jandus C.
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Publication state
Published
Issued date
2019
Peer-reviewed
Oui
Volume
10
Pages
2801
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.
Keywords
IL-33, ILC2, ST2, cancer, immunotherapy, patients
Pubmed
Open Access
Yes
Create date
19/12/2019 11:13
Last modification date
15/01/2021 7:08
Usage data